I do believe a few things:
1. They overpaid for MRS
2. They underdelivered in sales growth
3. They overpromised on acquisitions
4. They put out a carrot of a density FDA paper approval which never ever occurs
5. They talk of capitalising on COVID-19 opportunities and deliver ZILCH
6. They dilute existing holders at will and squander cash like no tomorrow
Investors need endless patience in this overpriced healthcare company.
- Forums
- ASX - By Stock
- VHT
- Ann: Volpara September Newsletter
Ann: Volpara September Newsletter, page-36
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)